Cybin Past Earnings Performance
Past criteria checks 0/6
Cybin's earnings have been declining at an average annual rate of -21.9%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually.
Key information
-21.9%
Earnings growth rate
1.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -28.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cybin makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -78 | 52 | 34 |
| 31 Mar 24 | 0 | -78 | 46 | 32 |
| 31 Dec 23 | 0 | -70 | 39 | 29 |
| 30 Sep 23 | 0 | -51 | 25 | 27 |
| 30 Jun 23 | 0 | -49 | 25 | 26 |
| 31 Mar 23 | 0 | -47 | 26 | 25 |
| 31 Dec 22 | 0 | -52 | 31 | 23 |
| 30 Sep 22 | 0 | -58 | 37 | 22 |
| 30 Jun 22 | 0 | -66 | 43 | 21 |
| 31 Mar 22 | 0 | -68 | 46 | 18 |
| 31 Dec 21 | 0 | -63 | 47 | 13 |
| 30 Sep 21 | 0 | -58 | 46 | 9 |
| 30 Jun 21 | 0 | -43 | 35 | 6 |
| 31 Mar 21 | 1 | -32 | 27 | 3 |
Quality Earnings: R7E is currently unprofitable.
Growing Profit Margin: R7E is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R7E is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare R7E's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: R7E is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: R7E has a negative Return on Equity (-28.01%), as it is currently unprofitable.